RxDoctor Payments Data

Xuanbo Chen

Family · Willow Springs, MONPI 1912676057

Payments from drug & device makers

$571in general payments, 2019–2025

Across 17 payments — averaging $33.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$361
  • Amgen$108
  • Exact Sciences$28
  • Lilly USA, LLC$20
  • Eisai Inc.$17
  • AbbVie$14
  • plus $24 from 2 others

What the payments were for

  • Food & beverage$571100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$571 in reported general payments places this provider in the 55th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$67,793
Medicare patients
207
Services billed
1,909

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide58$69,650
Trelegy ElliptaFluticasone/Umeclidin/Vilanter74$62,551
OzempicSemaglutide43$49,868
FarxigaDapagliflozin Propanediol48$39,839
EliquisApixaban50$38,456
Breztri AerosphereBudesonide/Glycopyr/Formoterol56$38,061
RexultiBrexpiprazole17$34,101
JardianceEmpagliflozin24$28,112
MounjaroTirzepatide15$22,163
Tresiba Flextouch U-200Insulin Degludec15$21,125
JanuviaSitagliptin Phosphate26$18,638
EntrestoSacubitril/Valsartan11$11,504
LinzessLinaclotide12$9,865
MyrbetriqMirabegron14$9,552
Breo ElliptaFluticasone/Vilanterol18$7,976

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$20$91,81473 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$361$81,303115 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$12$75,511106 claims
AbbVieLinzess$14$9,86512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,812 family providers in Missouri.

Other family in Willow Springs

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →